Caris Life Sciences (CAI) Stock Price & Analysis
Score
AI Analysis
SnapshotCaris Life Sciences is a growth-led story right now — Growth 86/100 is the pillar doing the heavy lifting (overall 66/100) in Biotechnology. Under the hood: P/E 98.9, rich vs its own history, plus revenue compounding ~50% annually over recent years. Street targets still imply ~24% upside.
Price History
Price: —
Fair value: —
—
P/E (TTM): —
Net Income (TTM): —
Score: —
—
Score Breakdown
Market percentile scores loading…
Value
Growth
Quality
Financial Summary
Caris Life Sciences, Inc. (CAI) last printed $23.04. Equity value is $6.61B. Trailing earnings multiple 68.79. The revenue row is reported history. Targets and ratings are on the forecast page.
Financials
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| $249.67M | $294.35M | $348.39M | $432.1M | $416.54M | $294.01M | $258.49M | $306.13M | $412.26M | $812.03M |
About
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.